Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check3 days agoChange DetectedSupplementary MedlinePlus references to lung cancer and genetics are no longer shown alongside the study’s resource links.SummaryDifference0.2%

- Check10 days agoChange DetectedThe study record for the pembrolizumab re-challenge trial is displayed, including its completed status, study details, eligibility criteria, locations, design, and outcome measures.SummaryDifference56%

- Check17 days agoChange DetectedThe site revision in the footer updates from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide notice links to updates and FAQs about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434.SummaryDifference1%

- Check30 days agoChange DetectedThe footer now displays site revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.